居住在欧洲的撒哈拉以南非洲及非洲苏里南裔慢性乙型肝炎患者的肝细胞癌风险
该国际多中心回顾性队列纳入荷兰、英国和西班牙的1473例撒哈拉以南非洲或非洲苏里南裔HBV单一感染者,中位随访8年,5年和10年肝细胞癌累积发生率分别为1%和2.4%,无晚期纤维化或基线(m)PAGE-B低评分者风险极低,可用于指导监测策略。
要点
- 5年和10年肝细胞癌累积发生率分别为1%和2.4%。
- 基线无晚期纤维化者10年累积发生率0.7%,有晚期纤维化者12.1%(p<0.001)。
- 基线PAGE-B低评分者10年累积发生率0.5%,中风险2.9%,高风险15.9%(p<0.001)。
核心结论
- 该国际多中心队列中撒哈拉以南非洲及非洲苏里南裔慢性乙型肝炎患者的5年和10年肝细胞癌累积风险分别为1%和2.4%。
- 基线无晚期纤维化或基线(m)PAGE-B低评分者肝细胞癌风险可忽略。
- 这些发现可用于指导肝细胞癌监测策略。
研究设计与样本
- 国际多中心回顾性队列研究,纳入荷兰、英国和西班牙中心连续管理的全部撒哈拉以南非洲或非洲苏里南裔HBV单一感染者。
- 共分析1473例个体,中位随访8年。
主要发现
- 中位随访8年期间,1473例中34例发生肝细胞癌。
- 5年和10年肝细胞癌累积发生率分别为1%和2.4%。
- 基线无晚期纤维化者10年累积发生率为0.7%,有晚期纤维化者为12.1%(p<0.001)。
- 年龄较高(aHR 1.05)、血小板计数较低(aHR 0.98)、白蛋白水平较低(aHR 0.90)和HBV DNA log10较高(aHR 1.21)与肝细胞癌发生显著相关。
- PAGE-B低评分者10年累积发生率为0.5%,中风险组为2.9%,高风险组为15.9%(p<0.001)。
关键数值与推荐
- 基线无晚期纤维化者10年肝细胞癌累积发生率0.7%,有晚期纤维化者12.1%(p<0.001)。
- PAGE-B低评分者10年累积发生率0.5%,中风险组2.9%,高风险组15.9%(p<0.001)。
- 年龄较高aHR 1.05、血小板计数较低aHR 0.98、白蛋白水平较低aHR 0.90、HBV DNA log10较高aHR 1.21与肝细胞癌发生显著相关。
临床怎么用
- 作者认为这些发现可用于指导该人群的肝细胞癌监测策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Sub-Saharan African (SSA) ethnicity has been associated with a higher risk of hepatocellular carcinoma (HCC) among individuals with chronic hepatitis B in cross-sectional studies. However, the incidence of HCC and performance of HCC risk scores in this population are unknown. METHODS: We conducted an international multicenter retrospective cohort study of all consecutive HBV-monoinfected individuals of SSA or Afro-Surinamese (AS) ethnicity managed at sites in the Netherlands, the United Kingdom and Spain. We assessed the 5- and 10-year cumulative incidences of HCC in the overall study population, among different clinically relevant subgroups and across (m)PAGE-B subgroups. Next, we explored the different risk factors for HCC. RESULTS: During a median follow-up of 8 years, we analyzed 1,473 individuals of whom 34 developed HCC. The 5- and 10-year cumulative incidences of HCC were 1% and 2.4%. The 10-year cumulative incidence of HCC was 0.7% among individuals without advanced fibrosis at baseline, compared to 12.1% among individuals with advanced fibrosis (p <0.001). Higher age (adjusted hazard ratio [aHR] 1.05), lower platelet count (aHR 0.98), lower albumin level (aHR 0.90) and higher HBV DNA log10 (aHR 1.21) were significantly associated with HCC development. The 10-year cumulative incidence of HCC was 0.5% among individuals with a low PAGE-B score, compared to 2.9% in the intermediate- and 15.9% in the high-risk groups (p <0.001). CONCLUSIONS: In this unique international multicenter cohort of SSA and AS individuals with chronic hepatitis B, we observed 5- and 10-year cumulative HCC risks of 1% and 2.4%, respectively. The risk of HCC was negligible for individuals without advanced fibrosis at baseline, and among individuals with low baseline (m)PAGE-B scores. These findings can be used to guide HCC surveillance strategies. IMPACT AND IMPLICATIONS: Sub-Saharan African ethnicity has been associated with a higher risk of hepatocellular carcinoma among individuals with chronic hepatitis B. In this international multicenter cohort study of sub-Saharan African and Afro-Surinamese individuals living with chronic hepatitis B in Europe, we observed 5- and 10-year cumulative incidences of hepatocellular carcinoma of 1% and 2.4%, respectively. The risk was negligible among individuals without advanced fibrosis and a low baseline (m)PAGE-B score. These findings can be used to guide HCC surveillance strategies in this population.
引用
- Patmore LA, van Eekhout KMA, Buti M, et al. Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe. J Hepatol. 2023. PMID: 37898348. doi:10.1016/j.jhep.2023.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。